Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Have Earned a 39% CAGR Over the Last Five Years
Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Have Earned a 39% CAGR Over the Last Five Years
Buying shares in the best businesses can build meaningful wealth for you and your family. While not every stock performs well, when investors win, they can win big. For example, the Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) share price is up a whopping 425% in the last half decade, a handsome return for long term holders. And this is just one example of the epic gains achieved by some long term investors. Also pleasing for shareholders was the 28% gain in the last three months.
购买最佳企业的股票可以为您和您的家人创造有意义的财富。尽管并非每只股票都表现良好,但当投资者获胜时,他们可以大获全胜。例如,细胞内疗法公司(纳斯达克股票代码:ITCI)的股价在过去五年中上涨了425%,对于长期持有者来说,这是一个可观的回报。这只是一些长期投资者取得巨大收益的一个例子。同样令股东高兴的是过去三个月的28%的涨幅。
Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.
让我们来看看长期的基本面,看看它们是否与股东的回报一致。
Because Intra-Cellular Therapies made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
由于细胞内疗法在过去十二个月中出现了亏损,因此我们认为至少目前市场可能更加关注收入和收入增长。无利可图的公司的股东通常期望强劲的收入增长。这是因为快速的收入增长可以很容易地推断出来预测利润,通常规模相当大。
In the last 5 years Intra-Cellular Therapies saw its revenue grow at 76% per year. Even measured against other revenue-focussed companies, that's a good result. Fortunately, the market has not missed this, and has pushed the share price up by 39% per year in that time. It's never too late to start following a top notch stock like Intra-Cellular Therapies, since some long term winners go on winning for decades. So we'd recommend you take a closer look at this one, but keep in mind the market seems optimistic.
在过去的5年中,细胞内疗法的收入以每年76%的速度增长。即使与其他注重收入的公司相比,这也是一个不错的结果。幸运的是,市场没有错过这一点,并在那段时间内将股价每年上涨39%。现在开始关注像Intra-Cellural Therapies这样的一流股票永远不会太晚,因为一些长期赢家持续赢了几十年。因此,我们建议您仔细研究一下,但请记住,市场似乎很乐观。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以在下面看到收入和收入如何随着时间的推移而变化(点击图片了解确切的值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240214/0-d067f3638952395acb8e81311efd416b-0-ca3eeaf795291fb91868fb5faa1c0423.png/big)
Intra-Cellular Therapies is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. You can see what analysts are predicting for Intra-Cellular Therapies in this interactive graph of future profit estimates.
细胞内疗法是一只众所周知的股票,有大量的分析师报道,这表明未来增长有一定的可见性。在这张未来利润估计的交互式图表中,您可以看到分析师对细胞内疗法的预测。
A Different Perspective
不同的视角
It's nice to see that Intra-Cellular Therapies shareholders have received a total shareholder return of 41% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 39% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. If you would like to research Intra-Cellular Therapies in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.
很高兴看到细胞内疗法股东去年获得的股东总回报率为41%。由于一年期股东总回报率好于五年期股东总回报率(后者为每年39%),因此该股的表现似乎在最近有所改善。鉴于股价势头仍然强劲,可能值得仔细研究该股,以免错过机会。如果你想更详细地研究细胞内疗法,那么你可能需要看看内部人士是否在买入或卖出该公司的股票。
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。